HOME > Investors > Press Releases
Subject ViroMed Announces PG201’s Potential Effect on Multiple Sclerosis in International Journal
Writer ViroMed
Date 2018/04/11


ViroMed Announces PG201’s Potential Effect on Multiple Sclerosis in International Journal

Company will seek US market entry where MS drug demand is high


April 2018, SEOUL, Korea – On April 11th, Korean biologics and phytotherapeutics developer ViroMed (KS: 084990) announced that the pre-clinical study results on its botanical drug PG201’s potential effect on multiple sclerosis (MS) has been published in the international scientific journal Phytomedicine.


PG201 was developed as a botanical drug for the treatment of osteoarthritis. It has been released in the market as a prescription drug under the brand name LaylaTM, with sales reaching KRW 22 billion in the Korean market.


The ViroMed research team had previously identified PG201’s strong anti-oxidant and anti-inflammatory activities, and after continuous follow-up research, confirmed that the drug could also be effective in treating MS. The study demonstrated that PG201 can reduce two different types of T cells which are pathogenetic factors in autoimmune inflammation, as well as interferon-gamma (IFN—γ) which is known to be a cause of abnormal inflammatory reaction. The drug was also found to delay disease progression in animal model.

MS is a type of autoimmune disease in which the body’s internal immune system attacks parts of its own tissues. Inflammation occurs in the central nervous system (CNS) and results in the damage of myelin, which serves a crucial role in the nervous system. There are about 2-2.5 million MS patients globally, and the disease is particularly prevalent in the US where it affects 1 out of 1,000 in the population aged 30 and above. Several treatment options are available, but with limited effects, which leads to high anticipation for new drugs. The global market research firm Research & Markets estimated that the MS treatment market was around KRW 18 trillion in 2016 and will surpass 30 KRW trillion by 2025.

A ViroMed representative commented, “With the company’s lead product VM202 already targeting several neurological diseases, we have established the foundations necessary for overseas clinical trials. As PG201 has proven its safety and efficacy in the Korean market for the past 6 years, and we plan to cautiously seek entry into the US market with the drug.”


Translation by English Editor

Original Korean text: http://www.sedaily.com/NewsView/1RY7RQ6FAZ